Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.

Journal of hematology & oncology - 17 Aug 2022

Elnaggar Muhammad, Agte Sarita, Restrepo Paula, Ram Meghana, Melnekoff David, Adamopoulos Christos, Stevens Mark M, Kappes Katerina, Leshchenko Violetta, Verina Daniel, Jagannath Sundar, Poulikakos Poulikos I, Parekh Samir, Laganà Alessandro

Abstract excerpt

BACKGROUND: Multiple Myeloma (MM) is a progressive plasma cell neoplasm characterized by heterogeneous clonal expansion. Despite promising response rates achieved with anti-BCMA CAR-T cell therapy, patients may still relapse and there are currently no clear therapeutic options in post-CAR-T settings. In this report, we present a case of a post-BCMA CAR-T relapsed/refractory (RR) MM patient with skin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation
Share to Immunotherapy, Adoptive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins B-raf

Share to Receptors, Chimeric Antigen

Share to Transplantation, Autologous

Source

Open in PubMed Open full text

Identifiers

PMID: 35978321
DOI: 10.1186/s13045-022-01330-3
PMCID: PMC9382834

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.PMID 35978321Read ↗

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.Semantic proximity Read ↗

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read ↗

Pathway-Directed Therapy in Multiple MyelomaSemantic proximity Read ↗

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Semantic proximity Read ↗

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma PatientsSemantic proximity Read ↗

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read ↗

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read ↗

Targeting the BRAF V600E mutation in multiple myeloma.Semantic proximity Read ↗

Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection TherapySemantic proximity Read ↗

Plasma cell myeloma with RAS/BRAF mutations: Clinicopathologic, molecular genetic features and outcomes of 68 patientsSemantic proximity Read ↗

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.Semantic proximity Read ↗

CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.